Literature DB >> 33965730

Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy.

Zijing Liu1, Qin Zhao1, Zhuangzhuang Zheng1, Shiyu Liu1, Lingbin Meng2, Lihua Dong3, Xin Jiang4.   

Abstract

Leakage and compression of blood vessels may result in deprivation of blood flow to a large number of tumor tissues, which can lead to tumor hypoxia. Hypoxia induces an increase in the expression of hypoxia-inducible factor 1 in tumor cells, which induces angiogenesis in tumors through the high expression of vascular endothelial growth factor, thereby forming a positive feedback vicious circle. Improving hypoxia by normalizing blood vessels and improving radiosensitivity by immunotherapy has emerged as a new application of combined immunotherapy and radiotherapy. Interferon γ produced by CD4 + /CD8 + T cells, induced by immune checkpoint inhibitors, plays an important role in the normalization of blood vessels; tumor-associated eosinophils also play a role in the process of immunotherapy-induced blood vessel normalization. In addition, the reduction in regulatory T cells induced by immune checkpoint inhibitors can increase eosinophil levels, which promotes the further development of vascular normalization mechanisms. This review focuses on the mechanism of immunotherapy to normalize blood vessels, and proposes a good prospect for improving hypoxia. Due to the narrow vascular normalization window of anti-angiogenesis therapy, discovery of the vascular normalization effect of immunotherapy provides a new idea for the combined application of immunotherapy and radiotherapy. The enlarged vascular normalization window and improved hypoxia provide a good opportunity for the subsequent implementation of radiotherapy. The above sorting and analysis may pave the way for a promising strategy for cancer treatment via combined immunotherapy and radiotherapy.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Hypoxia; Immune checkpoint inhibitors; Immunotherapy; Radiotherapy; Vascular normalization

Year:  2021        PMID: 33965730     DOI: 10.1016/j.biopha.2021.111607

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 2.  T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.

Authors:  Constantin N Baxevanis; Angelos D Gritzapis; Ioannis F Voutsas; Panagiota Batsaki; Maria Goulielmaki; Maria Adamaki; Vassilios Zoumpourlis; Sotirios P Fortis
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

3.  Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window.

Authors:  Fei Zhu; Wendong Yao; Yanjun Huang; Yanhong Chen; Zeng Wang; Xinjun Cai
Journal:  Ann Transl Med       Date:  2022-05

Review 4.  Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.

Authors:  Rosamaria Lappano; Lauren A Todd; Mia Stanic; Qi Cai; Marcello Maggiolini; Francesco Marincola; Violena Pietrobon
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

Review 5.  Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis.

Authors:  Hanying Zhou; Meng Wang; Yixi Zhang; Qingqing Su; Zhengxin Xie; Xiangyan Chen; Ran Yan; Ping Li; Tingting Li; Xiang Qin; Hong Yang; Chunhui Wu; Fengming You; Shun Li; Yiyao Liu
Journal:  Cancer Commun (Lond)       Date:  2022-04-26

6.  A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.

Authors:  Yue Shi; Min Ji; Yingying Jiang; Rong Yin; Zihan Wang; Hang Li; Shuaiyu Wang; Kang He; Yuxin Ma; Zhitong Wang; Jianwei Lu; Meiqi Shi; Bo Shen; Guoren Zhou; Tracy L Leong; Xiaohua Wang; Cheng Chen; Jifeng Feng
Journal:  Transl Lung Cancer Res       Date:  2022-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.